JACKSONVILLE, Fla.—Marco Ophthalmic, a leading ophthalmic technology company that is part of the Advancing Eyecare group, has entered into a distribution agreement with Olleyes, Inc., which offers intuitive and easy-to-use virtual reality ophthalmic products. Marco has added the Olleyes VisuALL S VRP (Virtual Reality Platform) into their existing portfolio of ophthalmic medical devices. The VisuALL is the latest commercially available virtual reality visual field analyzer that can be used in clinical practice to detect glaucoma and to evaluate other eye diseases. 

“The VisuALL is a multi-testing Virtual Reality Platform that increases doctors’ efficiencies. The platform brings several advantages over current technologies. Our alliance with Marco will help more clinicians and patients benefit from the VisuALL throughout the United States,” said Alberto Gonzalez-Garcia MD, CEO of Olleyes.

Armond Dantino, vice president of business development of Olleyes, remarked, “Marco is one of the largest and most respected suppliers of ophthalmic equipment and medical devices in the country, and Olleyes is extremely excited to enter into this distribution partnership. By expanding our distribution network throughout the United States, the VisuALL S VRP has potential to reach an additional 200 million people. Partnering with the Marco team helps Olleyes to realize our company’s vision of providing a comfortable, accurate, reliable, and cost-effective solution for administering visual diagnostics.” 

According to scientific studies and surveys, glaucoma is the most common cause of irreversible blindness. Based on prevalence studies, it is estimated that 79.6 million individuals had glaucoma by 2020, and this number is likely to increase to 111.8 million individuals in 2040. In many cases, glaucoma may be asymptomatic. Unfortunately, many individuals are unaware of the existence of glaucoma and as many as half of those with glaucoma are unaware that they are affected. In many cases, blindness can be prevented with appropriate control and treatment, and the VisuALL can help with early detection of these diseases, the company noted. More details are posted here.